<p>Comparing classification performance of the same assay with different TSI distribution and two different definitions of recency: at <i>t</i>* = 180 days (left bars) and <i>t</i>* = 365 days (right bars). With <i>u</i> = 0.2, sample size = 500, <i>h</i> = 500. The 95% prediction bounds are obtained from 1000 simulations.</p
Background: Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approv...
BACKGROUND: Assays and multi-assay algorithms (MAAs) have been developed for population-level cross-...
<div><p>Background</p><p>Multi-assay algorithms (MAAs) can be used to estimate HIV incidence in cros...
<p>Comparing classification performance of the same assay with different TSI distribution and differ...
<p>Comparing the mean performance (i.e., mean of <math><msub><mi>p</mi><mo>^</mo><mi>k</mi></msub></...
<div><p>Identifying recent HIV infection cases has important public health and clinical implications...
Identifying recent HIV infection cases has important public health and clinical implications. It is ...
Identifying recent HIV infection cases has important public health and clinical implications. It is ...
<p>With <i>u</i> = 0.2, sample size = 500, <i>h</i> = 500, recency at 6 months. The 95% prediction b...
<p>(<b>left</b>) Expected diversity evolution for different model behaviors, as determined by parame...
Background Cross-sectional, biomarker methods to determine HIV infection recency present a promisin...
Background: Cross-sectional, biomarker methods to determine HIV infection recency present a promisin...
BACKGROUND:Cross-sectional, biomarker methods to determine HIV infection recency present a promising...
HIV incidence is a primary metric for epidemic surveillance and prevention efficacy assessment. HIV ...
OBJECTIVE:HIV seroconversion biomarkers are being used in cross-sectional studies for HIV incidence ...
Background: Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approv...
BACKGROUND: Assays and multi-assay algorithms (MAAs) have been developed for population-level cross-...
<div><p>Background</p><p>Multi-assay algorithms (MAAs) can be used to estimate HIV incidence in cros...
<p>Comparing classification performance of the same assay with different TSI distribution and differ...
<p>Comparing the mean performance (i.e., mean of <math><msub><mi>p</mi><mo>^</mo><mi>k</mi></msub></...
<div><p>Identifying recent HIV infection cases has important public health and clinical implications...
Identifying recent HIV infection cases has important public health and clinical implications. It is ...
Identifying recent HIV infection cases has important public health and clinical implications. It is ...
<p>With <i>u</i> = 0.2, sample size = 500, <i>h</i> = 500, recency at 6 months. The 95% prediction b...
<p>(<b>left</b>) Expected diversity evolution for different model behaviors, as determined by parame...
Background Cross-sectional, biomarker methods to determine HIV infection recency present a promisin...
Background: Cross-sectional, biomarker methods to determine HIV infection recency present a promisin...
BACKGROUND:Cross-sectional, biomarker methods to determine HIV infection recency present a promising...
HIV incidence is a primary metric for epidemic surveillance and prevention efficacy assessment. HIV ...
OBJECTIVE:HIV seroconversion biomarkers are being used in cross-sectional studies for HIV incidence ...
Background: Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approv...
BACKGROUND: Assays and multi-assay algorithms (MAAs) have been developed for population-level cross-...
<div><p>Background</p><p>Multi-assay algorithms (MAAs) can be used to estimate HIV incidence in cros...